Exact Mass: 368.2563

Exact Mass Matches: 368.2563

Found 149 metabolites which its exact mass value is equals to given mass value 368.2563, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Cortol

(3R,5R,8S,9S,10S,11S,13S,14S,17R)-17-[(1S)-1,2-dihydroxyethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,11,17-triol

C21H36O5 (368.2563)


Involved in C21-Steroid hormone metabolism. [HMDB] Involved in C21-Steroid hormone metabolism.

   

Carboprost Tromethamine

1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9alpha,11beta,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-Oic acid

C21H36O5 (368.2563)


Carboprost Tromethamine is only found in individuals that have used or taken this drug. It is a nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy. [PubChem]Carboprost is a synthetic prostaglandin. It binds the prostaglandin E2 receptor, causing myometrial contractions, casuing the induction of labour or the expulsion of the placenta. Prostaglandins occur naturally in the body and act at several sites in the body including the womb (uterus). They act on the muscles of the womb, causing them to contract. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue

   

Cutamesine

Cutamesine

C23H32N2O2 (368.2464)


C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D018697 - Nootropic Agents

   

Misoprostol

9-oxo-11α,16-dihydroxy-16-methyl-prost-13E-en-1-oic acid

C21H36O5 (368.2563)


   

gamma-Eudesmol rhamnoside

2-{[2-(4a,8-dimethyl-1,2,3,4,4a,5,6,7-octahydronaphthalen-2-yl)propan-2-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


gamma-Eudesmol rhamnoside is a constituent of fruits of Cananga odorata (ylang ylang). Constituent of fruits of Cananga odorata (ylang ylang)

   

beta-Cortol

(1S,2S,5R,7R,10S,11S,14R,15S,17S)-14-[(1R)-1,2-dihydroxyethyl]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-5,14,17-triol

C21H36O5 (368.2563)


beta-Cortol is a normal androgen metabolite present in adults. It has been found in the urine of infants as well. Beta-Cortol is the 5b enantiomer of beta-allocortol. Beta-cortol levels are significantly higher in premenopausal women with leiomyomas than in age-matched healthy premenopausal control women. Uterine leiomyomas are tumors closely associated with estrogen levels and it has been noted that the development of leiomyomas depends on the condition of menstruation, perimenopause and pregnancy. (PMID: 14698830, 14616886, 14643447, 15635046, 14709852) [HMDB] beta-Cortol is a normal androgen metabolite present in adults. It has been found in the urine of infants as well. beta-Cortol is the 5beta enantiomer of beta-allocortol. beta-Cortol levels are significantly higher in premenopausal women with leiomyomas than in age-matched healthy premenopausal control women. Uterine leiomyomas are tumours closely associated with estrogen levels and it has been noted that the development of leiomyomas depends on the condition of menstruation, perimenopause, and pregnancy (PMID: 14698830, 14616886, 14643447, 15635046, 14709852).

   

Carboprost

7-[3,5-dihydroxy-2-(3-hydroxy-3-methyloct-1-en-1-yl)cyclopentyl]hept-5-enoic acid

C21H36O5 (368.2563)


   

Cutamesine

1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride

C23H32N2O2 (368.2464)


C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D018697 - Nootropic Agents

   

Misoprostol acid

7-[3-hydroxy-2-(4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl]heptanoic acid

C21H36O5 (368.2563)


   

Prostaglandin F2alpha methyl ester

Methyl 7-[3,5-dihydroxy-2-(3-hydroxyoct-1-en-1-yl)cyclopentyl]hept-5-enoic acid

C21H36O5 (368.2563)


   

Proterguride

3,3-diethyl-1-{6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl}urea

C22H32N4O (368.2576)


   

MG(18:2(10E,12Z)+=O(9)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (10E,12Z)-9-oxooctadeca-10,12-dienoic acid

C21H36O5 (368.2563)


MG(18:2(10E,12Z)+=O(9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(18:2(9Z,11E)+=O(13)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (9Z,11E)-13-oxooctadeca-9,11-dienoic acid

C21H36O5 (368.2563)


MG(18:2(9Z,11E)+=O(13)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(18:3(10,12,15)-OH(9)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoic acid

C21H36O5 (368.2563)


MG(18:3(10,12,15)-OH(9)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(18:3(9,11,15)-OH(13)/0:0/0:0)

(2S)-2,3-Dihydroxypropyl (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoic acid

C21H36O5 (368.2563)


MG(18:3(9,11,15)-OH(13)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/18:2(10E,12Z)+=O(9)/0:0)

1,3-Dihydroxypropan-2-yl (10E,12Z)-9-oxooctadeca-10,12-dienoic acid

C21H36O5 (368.2563)


MG(0:0/18:2(10E,12Z)+=O(9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/18:2(9Z,11E)+=O(13)/0:0)

1,3-Dihydroxypropan-2-yl (9Z,11E)-13-oxooctadeca-9,11-dienoic acid

C21H36O5 (368.2563)


MG(0:0/18:2(9Z,11E)+=O(13)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/18:3(10,12,15)-OH(9)/0:0)

1,3-Dihydroxypropan-2-yl (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoic acid

C21H36O5 (368.2563)


MG(0:0/18:3(10,12,15)-OH(9)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

MG(0:0/18:3(9,11,15)-OH(13)/0:0)

1,3-Dihydroxypropan-2-yl (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoic acid

C21H36O5 (368.2563)


MG(0:0/18:3(9,11,15)-OH(13)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).

   

Protoconstipatic acid

Protoconstipatic acid

C21H36O5 (368.2563)


   
   

Betaenone B

Betaenone B

C21H36O5 (368.2563)


   

DTXSID40920834

DTXSID40920834

C21H36O5 (368.2563)


   

ACMC-20mflt

ACMC-20mflt

C21H36O5 (368.2563)


   

Tomentogenin|Tomentogenin (5alpha-Dihydro-utendin)

Tomentogenin|Tomentogenin (5alpha-Dihydro-utendin)

C21H36O5 (368.2563)


   

(1beta,4alpha,5beta,6alpha,7alpha,10alpha)-10-Aromadendranol

(1beta,4alpha,5beta,6alpha,7alpha,10alpha)-10-Aromadendranol

C21H36O5 (368.2563)


   

14?鈥?Alcohol-Isomuronic acid

14?鈥?Alcohol-Isomuronic acid

C21H36O5 (368.2563)


   

tetrahydro-2-(14-hydroxypentadecyl)-4-methylene-5-oxo-3-furancarboxylic acid

tetrahydro-2-(14-hydroxypentadecyl)-4-methylene-5-oxo-3-furancarboxylic acid

C21H36O5 (368.2563)


   

methyl-2alpha,3alpha,9beta-trihydroxy-9-epi-labd-13(E)-en-15-oate

methyl-2alpha,3alpha,9beta-trihydroxy-9-epi-labd-13(E)-en-15-oate

C21H36O5 (368.2563)


   

(-)-dihydropertusaric acid|(-)589-Pertusarinic acid|(2S,3S,4S)-2,3,4,5-tetrahydro-4-methyl-5-oxo-2-(14-oxopentadecyl)furan-3-carboxylic acid|(3S,4S,5S)-4-carboxy-3-methyl-2-oxo-5-(14-oxopentadecyl)tetrahydrofuran

(-)-dihydropertusaric acid|(-)589-Pertusarinic acid|(2S,3S,4S)-2,3,4,5-tetrahydro-4-methyl-5-oxo-2-(14-oxopentadecyl)furan-3-carboxylic acid|(3S,4S,5S)-4-carboxy-3-methyl-2-oxo-5-(14-oxopentadecyl)tetrahydrofuran

C21H36O5 (368.2563)


   

beta-D-Fucopyranoside-1(10)-Spirovetiven-11-ol

beta-D-Fucopyranoside-1(10)-Spirovetiven-11-ol

C21H36O5 (368.2563)


   

Pretomexanthol

Pretomexanthol

C21H36O5 (368.2563)


   

3-hydroxy-2-(hydroxymethyl)-4-(14-methylpentadecanoyl)-2H-furan-5-one

3-hydroxy-2-(hydroxymethyl)-4-(14-methylpentadecanoyl)-2H-furan-5-one

C21H36O5 (368.2563)


   

Dinoprost methyl

Dinoprost methyl

C21H36O5 (368.2563)


   

RK-682, Streptomyces sp.

RK-682, Streptomyces sp.

C21H36O5 (368.2563)


   

agallochin M|methyl ent-13-epi-8,13-epoxy-4,6alpha-dihydroxy-3,4-secolabd-14-en-3-oate

agallochin M|methyl ent-13-epi-8,13-epoxy-4,6alpha-dihydroxy-3,4-secolabd-14-en-3-oate

C21H36O5 (368.2563)


   

(-)-PGE1 methyl ester|(-)-prostaglandin E1 methyl ester|methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-1-octenyl]-5-oxocyclopentyl]heptanoate|Methyl prostaglandin E1|PGE1 methyl ester|prostaglandin E1 methyl ester

(-)-PGE1 methyl ester|(-)-prostaglandin E1 methyl ester|methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-1-octenyl]-5-oxocyclopentyl]heptanoate|Methyl prostaglandin E1|PGE1 methyl ester|prostaglandin E1 methyl ester

C21H36O5 (368.2563)


   

(2S)-1-O-(9-oxo-10(E),12(E)-octadecadienoyl) glycerol

(2S)-1-O-(9-oxo-10(E),12(E)-octadecadienoyl) glycerol

C21H36O5 (368.2563)


   

2R,4R-diacetoxy-1-hydroxy-n-heptadeca-16-yne

2R,4R-diacetoxy-1-hydroxy-n-heptadeca-16-yne

C21H36O5 (368.2563)


   

sinularone I

sinularone I

C21H36O5 (368.2563)


   

1,2R-diacetoxy-4R-hydroxy-n-heptadeca-16-yne

1,2R-diacetoxy-4R-hydroxy-n-heptadeca-16-yne

C21H36O5 (368.2563)


   

1,4R-diacetoxy-2R-hydroxy-n-heptadec-16-yne

1,4R-diacetoxy-2R-hydroxy-n-heptadec-16-yne

C21H36O5 (368.2563)


   

(4S,5S,7R,10S)-Eudesm-11-en-4-ol beta-D-fucopyranoside

(4S,5S,7R,10S)-Eudesm-11-en-4-ol beta-D-fucopyranoside

C21H36O5 (368.2563)


   

Chaetomellic acid E

Chaetomellic acid E

C21H36O5 (368.2563)


   

Desacyl-kondurangogenin C; Dihydrodrevogenin D

Desacyl-kondurangogenin C; Dihydrodrevogenin D

C21H36O5 (368.2563)


   

11,12-didehydro-13-oxo-plakortide Q

11,12-didehydro-13-oxo-plakortide Q

C21H36O5 (368.2563)


   

17-Methoxy-1-propionyl-aspidospermidin|17-methoxy-1-propionyl-aspidospermidine|Palosine

17-Methoxy-1-propionyl-aspidospermidin|17-methoxy-1-propionyl-aspidospermidine|Palosine

C23H32N2O2 (368.2464)


   

Dihydropertusaric

Dihydropertusaric

C21H36O5 (368.2563)


   

Dihydromuronic acid

Dihydromuronic acid

C21H36O5 (368.2563)


   

Murolic acid

Murolic acid

C21H36O5 (368.2563)


   

Isomurolic acid

Isomurolic acid

C21H36O5 (368.2563)


   

Misoprostol (free acid)

9-oxo-11α,16-dihydroxy-16-methyl-prost-13E-en-1-oic acid

C21H36O5 (368.2563)


   
   

15-methyl-15(S)-PGE1

9-oxo-11R,15S-dihydroxy-15-methyl-13E-prostaenoic acid

C21H36O5 (368.2563)


   

PGF2&alpha

methyl 9S,11R,15S-trihydroxy-5Z,13E-prostadienoate

C21H36O5 (368.2563)


   

15(R)-15-methyl PGF2&alpha

9α,11α,15R-trihydroxy-15-methyl-prosta-5Z,13E-dien-1-oic acid

C21H36O5 (368.2563)


   

Carboprost

Carboprost

C21H36O5 (368.2563)


G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02A - Uterotonics > G02AD - Prostaglandins D012102 - Reproductive Control Agents > D000019 - Abortifacient Agents D012102 - Reproductive Control Agents > D010120 - Oxytocics C78568 - Prostaglandin Analogue

   

b-Cortol

5beta-Pregnane-3alpha,11beta,17,20beta,21-pentol 20beta-cortol

C21H36O5 (368.2563)


   

gamma-Eudesmol rhamnoside

2-{[2-(4a,8-dimethyl-1,2,3,4,4a,5,6,7-octahydronaphthalen-2-yl)propan-2-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

FA 21:3;O3

9S,11R,15R-trihydroxy-15-methyl-5Z,13E-prostadienoic acid

C21H36O5 (368.2563)


   

Cortol

Pregnane-3,11,17,20,21-pentol,(3a,5b,11b,20S)-

C21H36O5 (368.2563)


   

beta-Cortol

5beta-Pregnane-3alpha,11beta,17,20R,21-pentol

C21H36O5 (368.2563)


   

ST 21:0;O5

5alpha-pregnane-3alpha,11beta,17,20R,21-pentol

C21H36O5 (368.2563)


   

Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N,N-dicyclohexyl- (9CI)

Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N,N-dicyclohexyl- (9CI)

C22H32N4O (368.2576)


   

5a-pregnan-11b,17a,21-triol-3,20-dione-1,2,4,5-d4

5a-pregnan-11b,17a,21-triol-3,20-dione-1,2,4,5-d4

C21H28D4O5 (368.2501)


   

1-(tert-butyl)-3-(2,6-diisopropyl-4-phenoxyphenyl)urea

1-(tert-butyl)-3-(2,6-diisopropyl-4-phenoxyphenyl)urea

C23H32N2O2 (368.2464)


   
   

4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butan-1-ol

4-((5,6-diphenylpyrazin-2-yl)(perdeutero-propan-2-yl)amino)butan-1-ol

C23H20D7N3O (368.2593)


   

(16S,20S)-Pregnan-3beta,5alpha,6beta,16,20-pentaol

(16S,20S)-Pregnan-3beta,5alpha,6beta,16,20-pentaol

C21H36O5 (368.2563)


   

(3R,17R)-17-(1,2-dihydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,11,17-triol

(3R,17R)-17-(1,2-dihydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthrene-3,11,17-triol

C21H36O5 (368.2563)


   

Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, (11alpha,13E)-(+-)-

Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, (11alpha,13E)-(+-)-

C21H36O5 (368.2563)


   

15-methyl PGF2alpha

15-methyl PGF2alpha

C21H36O5 (368.2563)


   

Pgt-2A,methyl ester

Pgt-2A,methyl ester

C21H36O5 (368.2563)


   

MG(18:2(10E,12Z)+=O(9)/0:0/0:0)

MG(18:2(10E,12Z)+=O(9)/0:0/0:0)

C21H36O5 (368.2563)


   

MG(18:2(9Z,11E)+=O(13)/0:0/0:0)

MG(18:2(9Z,11E)+=O(13)/0:0/0:0)

C21H36O5 (368.2563)


   

MG(0:0/18:2(10E,12Z)+=O(9)/0:0)

MG(0:0/18:2(10E,12Z)+=O(9)/0:0)

C21H36O5 (368.2563)


   

[(2S)-2,3-dihydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

[(2S)-2,3-dihydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C21H36O5 (368.2563)


   

[(2S)-2,3-dihydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

[(2S)-2,3-dihydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C21H36O5 (368.2563)


   

1,3-dihydroxypropan-2-yl (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

1,3-dihydroxypropan-2-yl (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C21H36O5 (368.2563)


   

1,3-dihydroxypropan-2-yl (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

1,3-dihydroxypropan-2-yl (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C21H36O5 (368.2563)


   

Hinesol beta-D-fucopyranoside, (rel)-

Hinesol beta-D-fucopyranoside, (rel)-

C21H36O5 (368.2563)


A natural product found in Carthamus oxyacantha.

   

5-(Hydroxymethyl)-3-(1-oxohexadecyl)oxolane-2,4-dione

5-(Hydroxymethyl)-3-(1-oxohexadecyl)oxolane-2,4-dione

C21H36O5 (368.2563)


   

N-(cyclobutylmethyl)-N-[[(2S,3R,4S)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide

N-(cyclobutylmethyl)-N-[[(2S,3R,4S)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide

C23H32N2O2 (368.2464)


   

N-(cyclobutylmethyl)-N-[[(2R,3S,4R)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide

N-(cyclobutylmethyl)-N-[[(2R,3S,4R)-3-[4-(1-cyclopentenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]acetamide

C23H32N2O2 (368.2464)


   

3-Methyl-6-nonyl-6-(tetrahydro-2H-pyran-2-yloxymethyl)tetrahydro-2H-pyran-2,4-dione

3-Methyl-6-nonyl-6-(tetrahydro-2H-pyran-2-yloxymethyl)tetrahydro-2H-pyran-2,4-dione

C21H36O5 (368.2563)


   

(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate

(1-acetyloxy-3-hydroxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate

C21H36O5 (368.2563)


   

(2R)-2-[(14S)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

(2R)-2-[(14S)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

Prostaglandin F2alpha methyl ester

Prostaglandin F2alpha methyl ester

C21H36O5 (368.2563)


   

15-methyl-15S-Prostaglandin E1

15-methyl-15S-Prostaglandin E1

C21H36O5 (368.2563)


   

15-methyl-15R-PGF2alpha

15-methyl-15R-PGF2alpha

C21H36O5 (368.2563)


   

beta-Allocortol

beta-Allocortol

C21H36O5 (368.2563)


   

alpha-Allocortol

alpha-Allocortol

C21H36O5 (368.2563)


   

DG(18:2)

DG(8:0_10:2)

C21H36O5 (368.2563)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

IDF-11774

IDF-11774

C23H32N2O2 (368.2464)


IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65?μM.

   

(2r)-2,3-dihydroxypropyl (10e,12z)-9-oxooctadeca-10,12-dienoate

(2r)-2,3-dihydroxypropyl (10e,12z)-9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

(2r,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

(2r,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

(2s)-2,3-dihydroxypropyl 9-oxooctadeca-10,12-dienoate

(2s)-2,3-dihydroxypropyl 9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

(2s,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

(2s,3s)-2-[(14r)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

4-hydroxy-5-(hydroxymethyl)-3-(14-methylpentadecanoyl)-5h-furan-2-one

4-hydroxy-5-(hydroxymethyl)-3-(14-methylpentadecanoyl)-5h-furan-2-one

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6r)-2-({2-[(2r,4as)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-({2-[(2r,4as)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

(1r,2s,5s,6s,9r,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

(1r,2s,5s,6s,9r,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

C23H32N2O2 (368.2464)


   

agallochin m

NA

C21H36O5 (368.2563)


{"Ingredient_id": "HBIN014811","Ingredient_name": "agallochin m","Alias": "NA","Ingredient_formula": "C21H36O5","Ingredient_Smile": "CC1(CCC2C(O1)(CC(C(C2(C)CCC(=O)OC)C(C)(C)O)O)C)C=C","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "693","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101232173","DrugBank_id": "NA"}

   

alpha-bisabolol beta-d-fucopyranoside

NA

C21H36O5 (368.2563)


{"Ingredient_id": "HBIN015411","Ingredient_name": "alpha-bisabolol beta-d-fucopyranoside ","Alias": "NA","Ingredient_formula": "C21H36O5","Ingredient_Smile": "CC1C(C(C(C(O1)OC(C)(CCC=C(C)C)C2CCC(=CC2)C)O)O)O","Ingredient_weight": "368.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "19480","PubChem_id": "102286643","DrugBank_id": "NA"}

   

(2s,3r,4r,5r,6s)-2-({2-[(2r,4ar)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-({2-[(2r,4ar)-4a,8-dimethyl-2,3,4,5,6,7-hexahydro-1h-naphthalen-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

2-[(2-{6,10-dimethylspiro[4.5]dec-6-en-2-yl}propan-2-yl)oxy]-6-methyloxane-3,4,5-triol

2-[(2-{6,10-dimethylspiro[4.5]dec-6-en-2-yl}propan-2-yl)oxy]-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

methyl 3-[2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

methyl 3-[2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6r)-2-({2-[(2s,5s,10r)-6,10-dimethylspiro[4.5]dec-6-en-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-({2-[(2s,5s,10r)-6,10-dimethylspiro[4.5]dec-6-en-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

methyl 3-[(2r,4as,5s,6r,7r,8as)-2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

methyl 3-[(2r,4as,5s,6r,7r,8as)-2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

C21H36O5 (368.2563)


   

1-[(1r,9r,12r,19r)-12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl]propan-1-one

1-[(1r,9r,12r,19r)-12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl]propan-1-one

C23H32N2O2 (368.2464)


   

methyl 3-methyl-5-(1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl)pent-2-enoate

methyl 3-methyl-5-(1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl)pent-2-enoate

C21H36O5 (368.2563)


   

2-(14-hydroxypentadecyl)-4-methyl-5-oxo-2h-furan-3-carboxylic acid

2-(14-hydroxypentadecyl)-4-methyl-5-oxo-2h-furan-3-carboxylic acid

C21H36O5 (368.2563)


   

3-(hydroxymethyl)-6-(2-hydroxytetradecan-2-yl)-4-methoxypyran-2-one

3-(hydroxymethyl)-6-(2-hydroxytetradecan-2-yl)-4-methoxypyran-2-one

C21H36O5 (368.2563)


   

(2r,3r,4s,5r,6s)-2-methyl-6-{[(2s)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-yl]oxy}oxane-3,4,5-triol

(2r,3r,4s,5r,6s)-2-methyl-6-{[(2s)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-yl]oxy}oxane-3,4,5-triol

C21H36O5 (368.2563)


   

1-{12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl}propan-1-one

1-{12-ethyl-6-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6-trien-8-yl}propan-1-one

C23H32N2O2 (368.2464)


   

(2s)-2,3-dihydroxypropyl (10e,12e)-9-oxooctadeca-10,12-dienoate

(2s)-2,3-dihydroxypropyl (10e,12e)-9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

3-hexadecanoyl-4-hydroxy-5-(hydroxymethyl)-5h-furan-2-one

3-hexadecanoyl-4-hydroxy-5-(hydroxymethyl)-5h-furan-2-one

C21H36O5 (368.2563)


   

(9s)-3,9-dihydroxy-16,17-dimethoxytricyclo[12.3.1.1²,⁶]nonadecan-7-one

(9s)-3,9-dihydroxy-16,17-dimethoxytricyclo[12.3.1.1²,⁶]nonadecan-7-one

C21H36O5 (368.2563)


   

(2r)-2-[(14s)-14-hydroxypentadecyl]-4-methyl-5-oxo-2h-furan-3-carboxylic acid

(2r)-2-[(14s)-14-hydroxypentadecyl]-4-methyl-5-oxo-2h-furan-3-carboxylic acid

C21H36O5 (368.2563)


   

(2r,3s)-2-[(14s)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

(2r,3s)-2-[(14s)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

2-methyl-6-{[6-methyl-2-(4-methylcyclohex-3-en-1-yl)hept-5-en-2-yl]oxy}oxane-3,4,5-triol

2-methyl-6-{[6-methyl-2-(4-methylcyclohex-3-en-1-yl)hept-5-en-2-yl]oxy}oxane-3,4,5-triol

C21H36O5 (368.2563)


   

n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

C23H32N2O2 (368.2464)


   

(2s,3s,4s,5r,6s)-2-({2-[(2r,5s,10s)-6,10-dimethylspiro[4.5]dec-6-en-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

(2s,3s,4s,5r,6s)-2-({2-[(2r,5s,10s)-6,10-dimethylspiro[4.5]dec-6-en-2-yl]propan-2-yl}oxy)-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   
   

(2r)-2,3-dihydroxypropyl (10e,12e)-9-oxooctadeca-10,12-dienoate

(2r)-2,3-dihydroxypropyl (10e,12e)-9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

4-methyl-5-oxo-2-(14-oxopentadecyl)oxolane-3-carboxylic acid

4-methyl-5-oxo-2-(14-oxopentadecyl)oxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

(2r,3r,4s,5r,6s)-2-methyl-6-{[(2r)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-yl]oxy}oxane-3,4,5-triol

(2r,3r,4s,5r,6s)-2-methyl-6-{[(2r)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-yl]oxy}oxane-3,4,5-triol

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6r)-2-{[(4r,5r,6r,7s,10r)-7-isopropyl-4,10-dimethyltricyclo[4.4.0.0¹,⁵]decan-4-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-{[(4r,5r,6r,7s,10r)-7-isopropyl-4,10-dimethyltricyclo[4.4.0.0¹,⁵]decan-4-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

(2r)-2,3-dihydroxypropyl (9e,11e)-13-oxooctadeca-9,11-dienoate

(2r)-2,3-dihydroxypropyl (9e,11e)-13-oxooctadeca-9,11-dienoate

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6s)-2-{[(1r,4r,5r,6r,7s,10r)-7-isopropyl-4,10-dimethyltricyclo[4.4.0.0¹,⁵]decan-4-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6s)-2-{[(1r,4r,5r,6r,7s,10r)-7-isopropyl-4,10-dimethyltricyclo[4.4.0.0¹,⁵]decan-4-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6r)-2-{[(1s,4as,7r,8as)-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-{[(1s,4as,7r,8as)-1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

methyl 3-[(2r,4as,5s,6r,7s,8as)-2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

methyl 3-[(2r,4as,5s,6r,7s,8as)-2-ethenyl-7-hydroxy-6-(2-hydroxypropan-2-yl)-2,5,8a-trimethyl-hexahydro-1-benzopyran-5-yl]propanoate

C21H36O5 (368.2563)


   

(2s,3r,4s,5r,6r)-2-{[(1ar,4r,4as,7r,7as,7bs)-1,1,4,7-tetramethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-{[(1ar,4r,4as,7r,7as,7bs)-1,1,4,7-tetramethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)


   

2,3-dihydroxypropyl (9e,11e)-13-oxooctadeca-9,11-dienoate

2,3-dihydroxypropyl (9e,11e)-13-oxooctadeca-9,11-dienoate

C21H36O5 (368.2563)


   

methyl (2z)-5-[(1s,2r,4as,6s,7r,8as)-1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate

methyl (2z)-5-[(1s,2r,4as,6s,7r,8as)-1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate

C21H36O5 (368.2563)


   

(1r,2s,5s,6s,9r,12s,13r)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

(1r,2s,5s,6s,9r,12s,13r)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

C23H32N2O2 (368.2464)


   

(2s,3r)-2-[(14s)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

(2s,3r)-2-[(14s)-14-hydroxypentadecyl]-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

2-(14-hydroxypentadecyl)-4-methylidene-5-oxooxolane-3-carboxylic acid

2-(14-hydroxypentadecyl)-4-methylidene-5-oxooxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

(2r)-2,3-dihydroxypropyl (9z,11e)-13-oxooctadeca-9,11-dienoate

(2r)-2,3-dihydroxypropyl (9z,11e)-13-oxooctadeca-9,11-dienoate

C21H36O5 (368.2563)


   

(2s,3r,4s)-4-methyl-5-oxo-2-(14-oxopentadecyl)oxolane-3-carboxylic acid

(2s,3r,4s)-4-methyl-5-oxo-2-(14-oxopentadecyl)oxolane-3-carboxylic acid

C21H36O5 (368.2563)


   

2,3-dihydroxypropyl 13-oxooctadeca-9,11-dienoate

2,3-dihydroxypropyl 13-oxooctadeca-9,11-dienoate

C21H36O5 (368.2563)


   

pgf2α methyl ester

pgf2α methyl ester

C21H36O5 (368.2563)


   

(1r,2s,5s,6s,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

(1r,2s,5s,6s,12s,13s)-n,6,13-trimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-diene-7-carboximidic acid

C23H32N2O2 (368.2464)


   

methyl (2e)-5-[(1s,2r,4as,6s,7r,8as)-1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate

methyl (2e)-5-[(1s,2r,4as,6s,7r,8as)-1,6,7-trihydroxy-2,5,5,8a-tetramethyl-hexahydro-2h-naphthalen-1-yl]-3-methylpent-2-enoate

C21H36O5 (368.2563)


   

2-methyl-6-({1,1,4,7-tetramethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl}oxy)oxane-3,4,5-triol

2-methyl-6-({1,1,4,7-tetramethyl-octahydro-1ah-cyclopropa[e]azulen-4-yl}oxy)oxane-3,4,5-triol

C21H36O5 (368.2563)


   

(5r)-3-hexadecanoyl-4-hydroxy-5-(hydroxymethyl)-5h-furan-2-one

(5r)-3-hexadecanoyl-4-hydroxy-5-(hydroxymethyl)-5h-furan-2-one

C21H36O5 (368.2563)


   

2,3-dihydroxypropyl 9-oxooctadeca-10,12-dienoate

2,3-dihydroxypropyl 9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

2,3-dihydroxypropyl (10e)-9-oxooctadeca-10,12-dienoate

2,3-dihydroxypropyl (10e)-9-oxooctadeca-10,12-dienoate

C21H36O5 (368.2563)


   

2-{[1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-methyloxane-3,4,5-triol

2-{[1,4a-dimethyl-7-(prop-1-en-2-yl)-octahydronaphthalen-1-yl]oxy}-6-methyloxane-3,4,5-triol

C21H36O5 (368.2563)